CardioNet is one of those odd but revealing Medicare stories that sounds a little nerdy at first and then becomes genuinely suspenseful. On paper, it looked like a model growth company. It had an FDA-cleared product, strong sales, broad physician adoption, Medicare coverage, and the prestige boost of dedicated Category I CPT codes for mobile cardiovascular telemetry, effective January 1, 2009. Its patient-worn sensor and handheld wireless monitor let ECG data move continuously to a remote monitoring center, and the company’s finances looked like a classic medtech ramp: revenue rose from $73.0 million in 2007 to $120.5 million in 2008, with MCOT revenue of $100.2 million, or 83.2% of total revenue. Its March 2008 IPO raised about $81 million.[1] (SEC)
That is why the reimbursement crisis hit with such force. For the technical component, CPT 93229, Medicare did not initially set a national Part B price. Instead, the code was carrier-priced, with Highmark Medicare Services setting the amount on CMS’s behalf. In 2009, Highmark posted a rate of $1,123.07, which gave the company and investors every reason to think the Medicare economics would support continued growth. CardioNet itself presented that amount as the current technical reimbursement rate and linked it to its growth prospects.[2] (SEC)
Then came the first big break in the story. In 2009, Highmark reduced the Medicare reimbursement rate for MCOT to $754, effective September 1, 2009. CardioNet repeatedly described this as roughly a 33% reduction, and said the cut would have material adverse effects on the business. The company also made clear why this was not merely a Medicare bookkeeping problem: commercial payors had already begun pulling their own prices toward Medicare benchmarks, first toward the earlier $1,123.07 level and then, potentially, lower still. In 2009, CardioNet’s total revenue still rose to $140.6 million, but the old margin structure was broken.[3] (SEC)
One detail helps make the famous $754 number more intelligible. As Bruce Quinn has recalled, Highmark’s local medical director had noticed that CMS had already cross-walked the service on the hospital outpatient side to an ambulatory payment amount of about $753; once that number existed in another part of Medicare’s machinery, it became an easy local carrier benchmark to defend, even if it was analytically crude (B. Quinn, pers. comm.). That anecdote fits the broader documentary record very well. CMS later noted that the contractor’s price for CPT 93229 had “recently been reduced” in the area where most billings occurred, and the agency’s eventual national payment came in “close to the current typical contractor’s price.”[4] (Federal Register)
The market shock was severe because the company had looked so promising only months earlier. Local reporting from the Philadelphia Inquirer captured the drama: analyst Brian Kennedy warned in spring 2009 that Medicare reimbursement was likely to fall, management pushed back, and then the feared reduction arrived. The company that had seemed like a premium wireless-cardiology growth story suddenly looked like a reimbursement-dependent company with a cracked business model. That tone matches the company’s own disclosures in 2010, which emphasize restructuring, cost reductions, and operational stress after the rate cut.[5] (SEC)
The next twist was that CardioNet did get its national CPT code status, but not the quick national price reset it wanted. In late 2009, CMS did not establish a national reimbursement rate for 2010, leaving CPT 93229 still carrier-priced by Highmark. CardioNet publicly expressed disappointment, pointing out that the service had already been used in hundreds of thousands of patients nationwide. So after the 2009 reimbursement blow, the company did not get immediate rescue from the national physician fee schedule. The locally reduced price remained the operative benchmark for another year.[6] (Federal Register)
When CMS finally turned to national pricing for 2011, the problem became even more interesting. In the 2011 physician fee schedule final rule, CMS walked through the dispute over the practice expense inputs for CPT 93229. Commenters wanted CMS to treat a larger centralized monitoring infrastructure as direct practice expense. CMS refused. It said that, for CPT 93229, the only equipment item appropriately treated as a direct PE input was the cardiac telemetry monitoring device worn by the patient. The other items—software and hardware, workstation, webserver, call-recording system—were treated as indirect practice costs instead. CMS also said it would not depart from its standard PE methodology to build a special valuation for this code.[4] (Federal Register)
That technical fight points to the second Bruce Quinn insight, which is likely central to why the process dragged. The patient telemetry monitor appears to have had no easy, open-market clearing price; instead, the company could point mainly to its own internal transfer or cost-of-goods figures, perhaps in the range of $1,000 to $2,000, while CMS could reasonably wonder whether the true manufacturing cost might be far lower (B. Quinn, pers. comm.). That matters because the RVU practice-expense method is much more comfortable with inputs that look like ordinary public prices—an MRI scanner, a microscope, a reagent—than with a proprietary device whose “price” is mostly an internal accounting construct. CMS’s own description of PE methodology emphasizes this bottom-up framework of direct costs based on standardized equipment, supplies, and labor inputs, which makes CardioNet’s vertically integrated device a poor fit.[4] (Federal Register)
The outcome was predictable once seen in that light. In November 2010, CMS established a national rate of $739 per service for MCOT, effective January 1, 2011—close to the current contractor price, not a restoration of the old premium economics. CardioNet later said its 2012 geographic rate would be about $734. This was national pricing, yes, but it was national pricing that largely ratified the lower reimbursement world rather than reversing it.[3][7] (SEC)
Meanwhile, the financial damage accumulated. CardioNet’s 2009 revenue increase masked the fact that reimbursement pressure was eating away at margins. The company restructured, consolidated facilities, shifted manufacturing, and kept looking for operational savings. Then came another layer of crisis: in 2011 the company received a Civil Investigative Demand from DOJ regarding Medicare billing practices, and it later recorded a $45.999 million goodwill impairment tied to deterioration in the patient-services business.[7] (SEC)
The eventual outcome was not extinction, but mutation. CardioNet diversified away from the pure MCOT reimbursement thesis, acquired adjacent businesses, and reorganized into BioTelemetry. Over time, that broader platform proved much more resilient than the original one-product growth story. By 2019, BioTelemetry had sales of $439 million, and in December 2020 Philips agreed to acquire it in a deal with an implied enterprise value of about $2.8 billion. Philips completed the acquisition in February 2021.[8] (Philips)
In retrospect, the puzzle is engaging precisely because it is so Medicare-specific. CardioNet did not collapse because its technology stopped working. It had FDA, sales, adoption, and code status. What changed was the meaning of the service inside Medicare payment logic. First, its local contractor moved the price from $1,123.07 to $754, apparently aided by the comfort of an outpatient benchmark around $753 (B. Quinn, pers. comm.). Then CMS, facing a proprietary device without a clean market-clearing price and unwilling to capitalize most of the centralized infrastructure as direct practice expense, nationalized the code at $739 rather than restoring the old premium. That is a weird history, but also a revealing one: sometimes a booming medtech story turns not on FDA, or sales, or even clinical utility, but on whether Medicare believes the crucial inputs have the right kind of price.[3][4][7] (SEC)
References
[1] SEC S-1/A, CardioNet, Inc.
https://www.sec.gov/Archives/edgar/data/1113784/000104746908002538/a2179762zs-1a.htm
[2] CardioNet press release on posted reimbursement rate for CPT 93229.
https://www.biospace.com/cardionet-inc-announces-that-b-highmark-medicare-services-b-posts-reimbursement-rate-for-cpt-code-93229-mobile-cardiovascular-telemetry-services
[3] CardioNet 2011 Form 10-K, discussing reduction to $754 and later $739 national rate.
https://www.sec.gov/Archives/edgar/data/1113784/000104746912001348/a2207476z10-k.htm
[4] Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011, Federal Register.
https://www.federalregister.gov/documents/2010/11/29/2010-27969/medicare-program-payment-policies-under-the-physician-fee-schedule-and-other-revisions-to-part-b-for
[5] Philadelphia Inquirer, “Was analyst forced out for being right about CardioNet?”
https://www.inquirer.com/philly/blogs/inq-phillydeals/Was_analyst_forced_out_for_being_right_about_CardioNet.html
[6] Diagnostic and Interventional Cardiology, “CardioNet Provides Update on Mobile Cardiovascular Telemetry Reimbursement.”
https://www.dicardiology.com/content/cardionet-provides-update-mobile-cardiovascular-telemetry-reimbursement
[7] SEC filing discussing CMS national rate and 2011 business impact.
https://content.edgar-online.com/ExternalLink/EDGAR/0001047469-11-001414.html?dest=A2202163ZEX-10_38_HTM&hash=a332e0f64207f6cc607f0a6991c063a61458e69b2009fefea8d69a82d68f7077
[8] Philips announcement of acquisition of BioTelemetry.
https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html
###
###
SIDEBAR
Both Cardionet and iRhythm saw new codes that lagged several years in RVU pricing of PE.
For my records, Cardionet 93229 $759 represents a telemetry device EQ340, life 3 years, and capital cost $23,494. Used 28880 minutes valued at $1118 per use. (This is more than the total code price of $759 due to practice expense deflation factors that all pE pricing faces.) Turning to iRhythm, 93247 $253. The main valuation is supply (disposable) sD339 at $315. note again the PE cost is higher than the total PE final value of $253. By the way, 93247 is allowed a $1300 computer used 123 minutes for paltry amortized 65 cents. i can imagine why CMS was doubtful the Cardionet transmitter could cost $23494 and the little irhym patch for one lead ekg could cost $253.
Yes — that comparison is very revealing, and it sharpens the parallel nicely.
What your records show is that both disputes turned on PE inputs that looked implausible or at least vulnerable to skepticism when viewed from CMS’s side.
For CardioNet 93229, the striking feature is that the key direct PE item was not some ordinary office supply but a telemetry device, EQ340, assigned a 3-year life and a capital cost of $23,494, with 28,880 minutes of use and a resulting assigned cost of about $1,118 per use. As you note, that is already well above the final code payment of $759, because PE values are later compressed by the usual PE allocators and deflators. But before one even gets to those deflators, a CMS analyst is staring at a very expensive proprietary device and asking the obvious question: is this really a market-clearing equipment cost, or is it an internal accounting construct?
For iRhythm 93247, the structure is different but the skepticism point is similar. The main PE driver is not capital equipment but a disposable supply, SD339, priced at about $315, even though the final PE-derived code value is only about $253. Again, CMS is being asked to accept that the central physical input to the service costs more than the eventual PE-derived code amount. And, as you note, the code also includes a computer priced around $1,300 used for 123 minutes, contributing only about $0.65 on an amortized basis — essentially trivial. So the real valuation hinge is SD339. That makes the dispute even more concentrated: if CMS doubts SD339, it doubts the whole pricing architecture.
Put bluntly, one can easily imagine the CMS reaction in both eras:
CardioNet: “You are telling us this little telemetry monitor effectively carries a $23,494 equipment cost?” iRhythm: “You are telling us this one-lead adhesive patch effectively carries a $315 disposable cost?”
NOTE THAT - Those are not absurd on their face, but they are exactly the kind of inputs that trigger Medicare skepticism and delays when the pricing basis is proprietary, vertically integrated, or not clearly anchored in an open commercial market.
That is why your comparison is so good. The two cases differ in accounting category:
CardioNet: the contested PE driver is a capital equipment item.
iRhythm: the contested PE driver is a disposable supply item.
But economically, the disputes rhyme almost perfectly. In each case, the service’s RVU valuation depends heavily on a single proprietary physical input whose assigned price looks high relative to its apparent form factor and relative to ordinary medical-office intuitions. Once that happens, CMS’s instinct is to hesitate, ask for invoices, and avoid locking in a national price too quickly.
A crisp formulation for your records or blog would be:
CardioNet and iRhythm ran into the same Medicare nerve ending. In CardioNet, the problematic PE input was a telemetry device carried at $23,494 capital cost; in iRhythm, it was a disposable patch supply priced at $315. Different accounting buckets, same practical problem: CMS was asked to accept a high proprietary price for the key physical input to the service, and in both cases that invited skepticism and delay.
And an even punchier one:
CardioNet asked CMS to believe an expensive box. iRhythm asked CMS to believe an expensive sticker. In both cases, CMS blinked.
###
Chat GPT reviews the November 2022 final PFS rulewhich set 93247 pricing at about $250 based on an SD339 $315 patich.
###
Yes — this November 2022 / CY 2023 rulemaking strongly reinforces the lesson from the earlier CardioNet era.
What CMS says here is almost a case study in the same institutional reflex. For the iRhythm-related extended ECG codes, CMS explains that it did not receive a traditional invoice for SD339 at the outset, rejected higher-priced evidence such as clinical-study-marketplace invoices, and initially had only indirect or “top down” pricing approaches that yielded numbers in the $417–$440 range.
Because of the conflicting information, CMS left the key codes, including 93247, on local contractor pricing in 2021. It then kept soliciting more invoice data, set SD339 at $200.15 in the CY 2022 final rule based on ten invoices, but still did not nationalize pricing for 2022.
Only in the CY 2023 rule did it propose and finalize national pricing after accumulating more invoice support, ultimately finalizing SD339 at $260.35.
That is very revealing, because it shows CMS behaving exactly as one would infer from the older CardioNet episode. The problem was not simply whether the technology worked. The problem was whether CMS had a market-anchored direct PE input price it trusted enough to nationalize the RVUs.
In the CardioNet period, the sticking point was a proprietary telemetry monitor and related infrastructure that did not fit comfortably into a standard physician-office PE framework. Here, the disputed item is not a capital monitor but a disposable patch, SD339. But the pattern is the same: CMS is skeptical of top-down cost analyses, resistant to including delivery, software, processing, overhead, or R&D in direct PE, and insists on invoice-based evidence tied to the specific physical input. CMS says that the commenters’ broader cost studies “do not fit easily within the framework of how our PE methodology operates,” because those analyses include indirect expenses and R&D, which CMS does not treat as direct PE.
In that sense, the iRhythm record is almost a lessons learned sequel to CardioNet. CardioNet taught that CMS gets uneasy when a code’s valuation depends on a proprietary input whose price is hard to verify in an open market. iRhythm shows that, more than a decade later, CMS still responds the same way: delay national pricing, force the parties back toward invoice-based evidence, strip out indirect and R&D costs, and only then settle on a national amount. The nouns changed — EQ340 then, SD339 now — but the grammar stayed the same. A proprietary key input with a debatable price will slow or stall PE-based national valuation.
Some links
https://investors.irhythmtech.com/news/news-details/2022/iRhythm-Technologies-Comments-on-the-Announcement-of-the-Medicare-Physician-Fee-Schedule-Final-Rule-Released-by-the-Centers-for-Medicare-and-Medicaid-Services-for-Calendar-Year-2023/default.aspx
https://thecapitolforum.com/irhythm-cms-declines-new-pricing-for-ecg-monitoring-maintains-status-quo-pricing/
https://www.discoveriesinhealthpolicy.com/2020/08/cms-new-rules-rvu-system-facing-digital.html?m=1
https://www.discoveriesinhealthpolicy.com/2021/11/very-brief-blog-cms-publishes-final.html
A concise way to put it for your notes would be:
The CY 2023 iRhythm rulemaking confirms the old CardioNet lesson: when PE valuation turns on a proprietary physical input without a clean market price, CMS does not move quickly. It asks for invoices, rejects top-down enterprise cost models, strips out software and R&D, and may leave the code locally contractor-priced for years before nationalizing it.
